Janus Henderson Group PLC Buys 1,685,063 Shares of BioAge Labs, Inc. $BIOA

Janus Henderson Group PLC raised its stake in shares of BioAge Labs, Inc. (NASDAQ:BIOA) by 411.8% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,094,270 shares of the company’s stock after buying an additional 1,685,063 shares during the quarter. Janus Henderson Group PLC’s holdings in BioAge Labs were worth $36,597,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Quantinno Capital Management LP bought a new position in shares of BioAge Labs in the first quarter valued at approximately $404,000. Octagon Capital Advisors LP lifted its stake in BioAge Labs by 9.4% in the 1st quarter. Octagon Capital Advisors LP now owns 1,748,000 shares of the company’s stock worth $30,573,000 after purchasing an additional 150,000 shares in the last quarter. Renaissance Technologies LLC boosted its stake in BioAge Labs by 653.2% during the first quarter. Renaissance Technologies LLC now owns 138,588 shares of the company’s stock valued at $2,424,000 after buying an additional 120,188 shares during the period. Arrowstreet Capital Limited Partnership purchased a new stake in shares of BioAge Labs in the 1st quarter valued at about $1,537,000. Finally, Bank of Nova Scotia purchased a new stake in shares of BioAge Labs in the 1st quarter valued at about $180,000.

BioAge Labs Price Performance

Shares of BIOA stock opened at $9.04 on Monday. The business has a 50-day moving average price of $20.61 and a two-hundred day moving average price of $19.53. BioAge Labs, Inc. has a 12-month low of $4.11 and a 12-month high of $25.95. The firm has a market cap of $401.83 million, a P/E ratio of -3.77 and a beta of 0.94.

BioAge Labs (NASDAQ:BIOA) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.19. The firm had revenue of $2.77 million for the quarter. BioAge Labs had a negative return on equity of 29.40% and a negative net margin of 871.75%. As a group, research analysts expect that BioAge Labs, Inc. will post -2.68 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently commented on BIOA. Roth Capital reissued a “buy” rating and set a $25.00 price objective on shares of BioAge Labs in a report on Friday. BTIG Research started coverage on shares of BioAge Labs in a research note on Wednesday, May 13th. They issued a “buy” rating and a $40.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAge Labs in a research report on Tuesday, July 21st. Wall Street Zen cut shares of BioAge Labs from a “hold” rating to a “sell” rating in a research note on Sunday, May 17th. Finally, Needham & Company LLC decreased their price target on shares of BioAge Labs from $50.00 to $35.00 and set a “buy” rating on the stock in a report on Friday. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, BioAge Labs presently has a consensus rating of “Moderate Buy” and an average price target of $36.57.

BioAge Labs Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.